Precipio Provides Clarification To Amendment No.1 to Form S-1 Filing
January 28 2020 - 7:30AM
The management team of Specialty diagnostics company Precipio, Inc.
(NASDAQ: PRPO), would like to provide an explanation on the recent
Amendment to the S-1 that was filed yesterday, on January 27, 2020.
The company filed its S-1 registration statement
for the equity line by Lincoln Park on January 14, 2020. The
company received the SEC's confirmation of no-review, however, the
SEC requested that the company add a table with its executive
compensation updated as of December 31, 2019. The company complied
with this requirement by filing an amendment to the registration
statement and adding a new section "Executive Compensation" on page
27. This is the sole change from the registration statement that
was filed on January 14, 2019.
It is our understanding that following
completion and filing of this amended registration statement we
will be able to request from the SEC approval that the registration
statement is effective.
“We recognize that these filings can be complex,
and may require in-depth and timely review of company filings, as
well as substantial financial knowledge, in order to understand
these filings”, said Ilan Danieli, Precipio CEO. “We have decided
that as part of our effort to provide as much transparency, from
time to time the company will issue such press releases that help
provide clarification to our shareholders on the business
transactions we undertake.”
About Precipio
Precipio has built a platform designed to
eradicate the problem of misdiagnosis by harnessing the intellect,
expertise and technology developed within academic institutions and
delivering quality diagnostic information to physicians and their
patients worldwide. Through its collaborations with world-class
academic institutions specializing in cancer research, diagnostics
and treatment such as the Yale School of Medicine, Harvard’s
Dana-Farber Cancer Institute and the University of Pennsylvania,
Precipio offers a new standard of diagnostic accuracy enabling the
highest level of patient care. For more information, please visit
www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements,” within the meaning of
federal securities laws, including statements related to ICP
technology, including financial projections related thereto and
potential market opportunity, plans and prospects and other
statements containing the words “anticipate,” “intend,” “may,”
“plan,” “predict,” “will,” “would,” “could,” “should,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The Company’s actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Company’s definitive proxy
statement filed on May 29, 2018, the Company’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2019 and on the
Annual Report on Form 10-K for the year ended December 31, 2018 as
well as the Company’s prior filings and from time to time in the
Company’s subsequent filings with the Securities and Exchange
Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ
materially from those referred to in such statements. All
information in this press release is as of the date of the release
and the Company does not undertake any duty to update this
information, including any forward-looking statements, unless
required by law.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2023 to Apr 2024